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Introduction: Radiation oncologists were surveyed to assess prac-
tice patterns in the use of stereotactic body radiotherapy (SBRT) for 
lung cancer.
Methods: A customized patterns-of-care survey, consisting of 18 
questions and two clinical scenarios, was e-mailed to 136 academic 
radiation oncologists and 768 community practitioners to evaluate 
the technical basis and delivery parameters associated with SBRT.
Results: A total of 117 surveys were evaluable. The cited delivery 
techniques included: static noncoplanar beams (48%), intensity-modu-
lated radiotherapy (41%), rotational intensity-modulated radiotherapy 
(47%), dynamic conformal arcs (7%), and small-beam delivery with 
fiducial tracking (24%), with 46% using multiple techniques. The 
immobilization methods included: stereotactic frame (10%), alpha cra-
dle or vacuum-lock system (52%), wingboard (3%), stereotactic frame 
with an alpha cradle or vacuum-lock system (11%); combination of 
devices (14%), or no immobilization (9%). Abdominal compression 
was used by 51% and respiratory gating by 31%. For a peripheral 
T1N0 tumor, the preferred doses included: 25 to 34 Gy in one fraction 
(1%); 54 to 60 Gy in three fractions (56%), 48 to 50 Gy in four frac-
tions (18%), and 50 to 60 Gy in five fractions (25%). For a centrally 
located T1N0 tumor, 58% recommended SBRT outside a clinical pro-
tocol, with recommended doses ranging from 40 to 60 Gy in three to 
10 fractions. The recommended interval to first surveillance imaging 
ranged from 6 weeks or lesser (32%) to 25 weeks or more (2%).
Conclusions: Considerable variation exists for thoracic SBRT with 
regard to dose selection, fractionation, immobilization, planning, 
management of central lesions, and surveillance. Ongoing prospec-
tive evaluation is recommended to identify best practices and provide 
continual process improvement.
Key Words: Lung cancer, Stereotactic body radiotherapy, 
Patterns-of-care.
(J Thorac Oncol. 2013;8: 202–207)
Over the past decade, stereotactic body radiotherapy (SBRT) has emerged as the standard of care for 
medically inoperable patients with early-stage non–small-
cell lung cancer (NSCLC). The first published reports 
using SBRT for thoracic tumors, originating from the 
Karolinska Institute1 and the National Defense Medical 
College of Japan,2 demonstrated promising clinical effi-
cacy. Subsequent prospective trials established high rates 
of local control and low toxicity.3,4 Two landmark prospec-
tive trials, the Radiation Therapy Oncology Group (RTOG) 
0236 and the Nordic Study Group Phase II, demonstrated 
local control exceeding 90% at 3 years using three-fraction 
regimens.5,6 With high-level, prospective evidence demon-
strating impressive local control and low toxicity, SBRT 
has been widely and rapidly adopted by radiation oncology 
centers around the United States. An earlier survey per-
formed by investigators at the University of California, San 
Diego, suggests that more than 60% of radiation oncolo-
gists in the United States have incorporated SBRT into their 
clinical practice for one or more anatomical sites, with the 
majority of SBRT practitioners (89%) treating lung cancer 
patients.7
With the widespread implementation of SBRT, a 
variety of dosimetric planning approaches, immobilization 
techniques, fractionation schemes, and surveillance 
strategies have emerged. As SBRT depends critically 
upon precise target localization and delivery of a high 
biologically effective dose per fraction with a steep dose 
gradient and tight margins, technical aspects of treatment, 
such as image guidance and motion management, are 
of particular relevance. Management of the subgroup of 
patients with centrally located (defined as within 2 cm of the 
proximal bronchial tree) tumors using SBRT also remains 
controversial after reports of unacceptable toxicity after 
treatment with 54 to 60 Gy in three fractions.8,9 The American 
Association of Physicists in Medicine (AAPM) Task Group 
101 has outlined recommendations for immobilization, 
image guidance, and treatment delivery.10 However, rates of 
adherence to these guidelines are unknown. Given the many 
uncertainties regarding the technical planning and delivery 
of thoracic SBRT, the aim of the present study was to assess 
specific patterns-of-care across the United States, with a 
focus on planning strategies, motion management, dose and 
fractionation, and posttreatment surveillance.
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MATERIALS AND METHODS
Patterns-of-Care Survey
After procuring Institutional Review Board approval, a 
link to a customized, web-based patterns-of-care survey was 
e-mailed to 136 academic thoracic radiation oncologists and 
768 community-based radiation oncologists. Survey recipients 
included all thoracic radiation oncologists practicing in the 
United States, as identified from academic department web-
sites. Community-based practitioners were randomly selected 
from the American Society for Radiation Oncology website 
directory. Survey recipients included physicians practicing in 
all the 50 states and Puerto Rico. The original survey included 
18 multiple-choice questions followed by two clinical scenar-
ios: a peripheral T1aN0 NSCLC and a centrally located T1aN0 
NSCLC (Fig. 1A and B). The questions assessed respondents’ 
SBRT practice demographics, case volume, immobiliza-
tion methods, planning technique, fractionation schedules, 
motion-management approach, target localization, and post-
treatment surveillance strategy. The full contents of the survey 
are included in Appendix 1. The intended respondents were 
practitioners currently using SBRT. Responses were collected 
in aggregate between June 22, 2012 and April 4, 2012, with 
no personal identifiers.
Statistical Analysis
Surveys were considered evaluable if at least one ques-
tion was answered, and if the respondent indicated that he/she 
performed SBRT as a part of their practice. Survey results are 
indicated in the percentage of evaluable responses for each 
question. Two by two contingency tables were used to assess 
differences between survey reponses of specific groups using 
Fisher’s exact test, with a two-tailed significance level of p 
value of 0.05 or lesser. All calculations were performed with 
GraphPad (GraphPad Software, Inc. La Jolla, CA).
RESULTS
Respondent Demographics
A total of 117 surveys were evaluable among 46 aca-
demic physicians (39%), 58 community physicians (50%), 
and 13 hybrid or other (11%), for a response rate of 13%. 
Survey respondents practiced in 36 different states and in 
the District of Columbia. Ninety-four percent of the physi-
cians surveyed were board certified. Fourteen percent have 
practiced for less than 2 years and 49% for 10 or more years. 
Eighteen percent performed fewer than five SBRT cases in a 
year, whereas 28% performed more than 30 cases in a year. 
Full respondent demographics are outlined in Table 1.
Immobilization and Treatment Planning
The reported methods of immobilization include stereo-






























SBRT, stereotactic body radiotherapy.
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system alone (52%), wingboard alone (3%), stereotactic body 
frame with an alpha cradle or vacuum-lock system (11%); 
combination of devices (14%), or no immobilization (9%). All 
respondents who reported not using a patient immobilization 
device used multiple small-beam delivery systems with tumor 
and/or fiducial tracking. Seventy-eight percent of respondents 
reported obtaining four-dimensional computed tomography 
(4DCT) for SBRT planning in all cases, and 8% obtained 
4DCT for select cases.
The majority of respondents (54%) reported use of mul-
tiple planning techniques in their practice. The cited SBRT 
delivery techniques included: static noncoplanar beams (48%), 
static intensity-modulated radiotherapy (IMRT) (41%), rota-
tional IMRT (47%), dynamic conformal arcs (7%), multiple 
small-beam delivery with fiducial tracking (24%), and protons 
(1%). Planning was performed with heterogeneity correction 
by 94%. Ninety-seven percent of respondents prescribed dose 
volumetrically, whereas 3% prescribed to a point. Eighty-five 
percent performed a patient-specific quality assurance check 
for every SBRT case. Details of immobilization and treatment 
planning are summarized in Table 2.
Motion Management and Treatment Delivery
Nineteen percent of surveyed physicians preferred to 
deliver fractions on consecutive days, 58% on nonconsecutive 
days, and 23% on a case-dependent basis. Motion-
management strategies included abdominal compression for 
51%, respiratory gating for 31%, breath-hold techniques for 
13%, implanted fiducial tracking for 24%, and implanted 
real-time transponder tracking for 1%. Twenty-nine percent 
incorporated multiple motion-management strategies in their 
practice. All responding physicians reported using some 
form of image-guided radiotherapy. Seventy-eight percent 
obtained a pretreatment conebeam computed tomography 
(CBCT) before each fraction, whereas 14% also obtained 
a mid-fraction CBCT, 2% obtained a CBCT at completion 
of each fraction, and 2% obtained a CBCT both mid- and 
posttreatment. Twenty-four percent used real-time fiducial 
tracking, 2% obtained an orthogonal kilovoltage image 
pair alone, and 1% used electronic portal imaging alone. 
Fluoroscopy was performed before each fraction by 13% and 
for select cases by 7%, to assess diaphragm or tumor motion.
Clinical Case Management
The first clinical scenario described a 79-year-old male 
patient with a 1.5 cm, peripherally located grade 2 adenocarci-
noma of the left upper lobe of the lung, positioned 1.2 cm from 
the chest wall (Fig. 1A). The preferred fractionation schemes 
ranged from 25 to 34 Gy in one fraction (1%) to 50 to 60 Gy 
in five fractions (25%), with the 54 to 60 Gy in three fractions 
selected most frequently (56%).
The second clinical scenario presented a 72-year-old man 
with a medically inoperable 1.8 cm right upper lobe, central 
squamous cell carcinoma, located 1.0 cm from the trachea and 
touching the mediastinal pleura (Fig. 1B). Ninety-nine percent 
of respondents recommended staging beyond computed tomog-
raphy for a central lesion, including positron emission tomog-
raphy (PET) alone (14%), PET with pathologic mediastinal 
staging through mediastinoscopy or endobronchial ultrasound 
only if abnormalities by PET (53%), and PET with pathologic 
staging of the mediastinum regardless of PET findings (32%). 
Assuming a negative mediastinal workup, 58% of respondents 
recommended SBRT in the absence of a clinical protocol. An 
additional 23% would offer SBRT on clinical protocol, and 
18% would only offer conventional fractionation. Among those 
advocating SBRT, recommended doses ranged from 54 to 60 Gy 
in three fractions (7%), to 60 Gy in eight to 10 fractions (9%), 
with 50 to 55 Gy in five selected frequently (65%). Fractionation 
preferences for the peripheral and central cases are summarized 
in Figure 2. No difference in comfort delivering SBRT to a 
central lesion off-protocol was noted between academic practi-
tioners and those in community or hybrid practices (p = 0.84), 
between those in practice for 10 years or more compared with 
those in practice for more than 10 years (p = 0.45), or between 
those treating 20 or more lung SBRT cases in a year and those 
treating fewer than 20 cases in a year (p = 0.24).
The recommended interval from completion of SBRT 
to the first follow-up imaging study ranged from 6 weeks or 
lesser (32%) to 25 weeks or more (2%). Forty-two percent 
of surveyed physicians preferred computed tomography 
(CT) alone for surveillance, 24% prefer PET or CT, and 34% 
obtained both. No significant difference in likelihood to obtain 
PET or CT surveillance was identified between academic and 
private or hybrid practitioners (p = 0.18). Details of surveil-
lance strategies are summarized in Table 3.
DISCUSSION
The aims of the present study were to assess current 
practice patterns for thoracic SBRT among radiation oncolo-
gists practicing in the United States, with a focus on techni-
cal planning and delivery parameters in the setting of clinical 
TABLE 2.  Immobilization and Treatment Planning 
Immobilization Percent
Stereotactic body frame 10
Alpha cradle/vacuum-lock 52
Wingboard 3
Stereotactic body frame and alpha cradle/vacuum-lock 11
Alpha cradle/vacuum-lock and wingboard 11
Stereotactic body frame, alpha cradle/vacuum-lock and wingboard 3
No immobilization 9
Planning techniques
 Static noncomplanar beams 48
 Static IMRT 41
 Rotational IMRT 47
 Dynamic conformal arcs 7





IMRT, Intensity modulated radiotherapy; SBRT, stereotactic body radiotherapy.
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decision making. The survey did not attempt to assess the 
prevalence of SBRT use, which has already been evaluated by 
several published surveys.7,11 A balanced blend of academic 
thoracic specialists and community practitioners responded, 
with caseloads ranging from less than five to more than thirty 
thoracic SBRT cases in a year.
Treatment planning approaches, immobilization, and 
motion-management strategies varied significantly among 
respondents, with many using multiple treatment platforms 
and approaches to motion management. The majority of 
respondents reported immobilization with a stereotactic 
body frame or a rigid pillow device (vacuum-lock or alpha 
cradle), consistent with guidelines from current RTOG 
protocols. Image guidance strategies varied significantly, 
ranging from two-dimensional portal imaging alone to pre-, 
mid-, and posttreatment volumetric CT. More than three 
quarters of respondents used 4DCT simulation to assist with 
internal target volume delineation. Because variations in 
immobilization, simulation, motion management, and image 
guidance definitely have implications as to the appropriate 
internal target volume and planning target volume margins, 
the practice of adopting margins adequate in clinical trials, 
using more rigorous immobilization and image guidance, 
may be inappropriate for centers with less rigorous strategies. 
Care should be taken when implementing protocol-based 
guidelines for target volumes and normal tissue constraints if 
the immobilization and image guidance from those protocols 
are not used. The AAPM Task Group 101 report outlines 
best practice guidelines for the implementation of SBRT, 
and suggests that volumetric image guidance strategies 
coupled with “integrated image-based monitoring systems or 
aggressive immobilization” are mandatory.10 Our data suggest 
that not all centers adhere to the AAPM guidelines.
Treatment planning with static noncoplanar beams, 
as used in the early studies from Indiana University and 
the RTOG,3,5 remained the most often observed approach. 
However, approaches involving beam modulation, including 
static and rotational IMRT, were heavily used (41% and 47%, 
respectively). Multiple small-beam delivery systems with 
fiducial tracking were used by nearly a quarter of respondents. 
Early concerns regarding the interplay of intensity-modulated 
beams and a moving target seem unfounded, given the recent 
dosimetric analyses with four-dimensional dose modeling 
suggesting that the impact is negligible, even with large doses 
per fraction.12 The widespread use of intensity-modulated 
planning strategies suggests that such concerns are abating 
among practitioners. Survey results suggested that heteroge-
neity correction has been widely adopted and that virtually all 
practitioners (97%) now prescribe dose volumetrically. Both 
these steps are important toward accurately and consistently 
reporting delivered dose.
Current National Comprehensive Cancer Network 
guidelines for thoracic SBRT list a range of suggested frac-
tionation schemes. For peripherally located tumors, these 
include 25 to 34 Gy in one fraction for small tumors (<2 cm) 
located less than 1 cm from the chest wall, 45 to 60 Gy in 
three fractions, 48 to 50 Gy in four fractions, and 50 to 55 
Gy in five fractions.13 Recommended regimens for central 
tumors include 48 to 50 Gy in four fractions, 50 to 55 Gy in 
five fractions, and 60 to 70 Gy in eight to 10 fractions. The 
recommendation for more protracted regimens for centrally 
located tumors largely stems from the results of a phase II 
trial performed at Indiana University, demonstrating excess 
toxicity with delivery of 60 to 66 Gy in three fractions to cen-
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strategies for centrally located tumors suggest that more pro-
tracted regimens of four to eight fractions are both safe and 
efficacious.14–19 The currently accruing RTOG 0813 protocol 
will assess a five-fraction dose-escalation scheme for centrally 
located tumors. Our data confirm that, although a sizeable 
minority of practitioners remain hesitant to implement SBRT 
for centrally located tumors outside the setting of a clinical 
trial, more than half (59%) of them would recommend SBRT 
for a central tumor off-protocol, and 93% of those who did, 
preferred a regimen of four or more fractions.
For the presented peripheral lesion, the most often 
selected dose was the three-fraction regimen of 54 to 60 Gy 
used by RTOG 0236. Interestingly, despite the convenience, 
the reported safety and efficacy,4,20,21 and inclusion in the 
National Comprehensive Cancer Network guidelines as an 
appropriate treatment option, a single-fraction regimen of 
25 to 34 Gy was selected by only 1% of respondents for the 
small, peripheral tumor. Publication of the randomized RTOG 
0915, comparing 34 Gy in a single fraction or 48 Gy in four 
fractions and closed to accrual as of March 2011, should pro-
vide much-awaited randomized evidence as to the preferred 
fractionation scheme for peripheral tumors.
Few evidence-based guidelines exist as to the optimal 
posttreatment surveillance strategy, and correspondingly, sur-
vey respondents report varying approaches. The optimal tim-
ing of posttreatment imaging remains an open question, and 
respondents ranged from less than 4 to 25 weeks or more as 
their preferred first posttreatment imaging study. Thirty-two 
percent of respondents, however, report first surveillance 
imaging within the first 6 weeks. Few specific data exist to 
determine optimal timing of the first posttreatment imaging. 
However, reports from published prospective trials suggesting 
failure within the first 3 months are exceedingly rare,3,5,6,14,21 
and correspondingly, that restaging within the first 3 months 
has scant evidence-based support. Further prospective evalua-
tions of the optimal surveillance approach are sorely needed. 
The integration of posttreatment PET or CT was advocated 
by 58% of respondents. Data for posttreatment PET or CT are 
largely retrospective, with some studies suggesting prognos-
tic value22,23 and others failing to demonstrate utility.24 Further 
prospective data as to the optimal modality and timing of post-
SBRT imaging are greatly needed.
The limitations of the present study include a potentially 
biased respondent pool, as academic thoracic radiation 
oncologists were specifically selected as survey recipients. 
In addition, the fairly low overall response rate of only 13% 
may create additional bias, as physicians with certain practice 
patterns may have elected to respond. We identified academic 
survey recipients on the basis of a thoracic disease site focus, 
which likely increased our survey yield among academic 
practitioners, whereas community practitioners were 
randomly identified from the American Society for Radiation 
Oncology directory, and very likely included many physicians 
not currently performing SBRT. Thus, not surprisingly, the 
response rate among academic physicians was significantly 
higher than among community physicians, adding an 
additional potential selection bias. Future survey efforts could 
include additional measures to increase response rate, such 
as additional contact with nonresponders through e-mail or 
phone, or incentivizing response. In addition, respondents were 
allowed to select multiple options for questions dealing with 
treatment planning, motion management, and immobilization, 
which led to some difficulties in interpretation. Nonetheless, 
the survey results provide a provocative indication of the wide 
range of practice patterns currently in use for thoracic SBRT.
CONCLUSIONS
Considerable physician variation exists in the technical 
delivery of thoracic SBRT with respect to such factors as dose 
selection, fractionation, immobilization, planning methods, 
management of central lesions, and follow-up strategy. Our 
findings highlight the need for not only continual evaluation 
and refinement of the SBRT process, but also for standardiza-
tion of the planning and delivery process, which may better 
guide physicians in clinical practice. Until then, ongoing and 
future prospective trials should better delineate optimal frac-
tionation schemes and posttreatment surveillance approaches.
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